Navigation Links
ReBuilder Medical Technologies, Inc.'s Recent Stock Price Volatility Explained
Date:11/23/2007

Unique Buying Opportunity Presented

CHARLES TOWN, W.Va., Nov. 23 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM), a provider of treatment for diabetic peripheral neuropathy and Molluscum Contagiosum, today announced it has successfully concluded analysis of the recent volatility of their stock price and presented it to the Board of Directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )

It appears that several institutional and corporate investors possibly got nervous over the sub-prime housing crisis and liquidated large portions of their portfolios. "Unfortunately, our equity was included in their programmed liquidation process. As a result, many individual investors followed suit, increasing the supply of stock available to purchase and driving down the price per share," according to David Phillips, Ph.D. CEO.

Meanwhile the company continued its steady growth as evidenced by the quarterly reports published on pinksheets.com. There was no bad news whatsoever relative to the actual operations of the company. "We are in better financial shape, in better marketing shape, in better R&D shape, and in better PR shape than ever before in our company's history," says Dr. Phillips.

"We have successfully renegotiated certain aspects of our original merger terms to reduce the possibility of any remaining large corporate holders of our equities from taking profits and dumping large blocks of our stock on the market. In addition, many of these original holders of large blocks of our equities have now liquidated the majority of their shares to individual investors. We expect that these new individuals may have the best long-term interests of our company in mind. This could have the desired effect of stabilizing the stock price and thus reflect the real value of our equities," st
'/>"/>

SOURCE ReBuilder Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...- Biomedical engineers at The University of Texas ...ave announced pre-clinical test results in the Sep...edicine demonstrating the feasibility of a smart p... in glucose or blood sugar levels and releases ins...tions of the pancreas which produces the blood-sug...
...nc. (Nasdaq:,SQNM) today announced that a live aud...l be provided for its analyst and investor briefin...the event are as follows: (Logo: http://www.new... Sequenom Today and Tomorrow, When: Monday...here: http://www.sequenom.com , How: Liv...
...l Alliance, the leading,management consulting firm...dustries, today announced that Ben Bonifant, Vice ...ent practice, will moderate a panel discussion,at ...rence hosted by,Windhover Information. The confere...iott Financial Center in New York City. The panel...
Other Biology Technology:Smart insulin nanostructures pass feasibility test, UT study reports 2Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24 2Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference 2Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference 3
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/4/2009)Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of h
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):How to read brain activity? 2U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Biopolymers Symposium 2009 Teams with Carbonfund org to Create a Zero Carbon Event 13295 1Biopolymers Symposium 2009 Teams with Carbonfund org to Create a Zero Carbon Event 13295 210 Steps to Affordable Health Care Overhaul 3A NCPA Proposes Reforms to Protect Choices Control Costs and Preserve Access 53252 110 Steps to Affordable Health Care Overhaul 3A NCPA Proposes Reforms to Protect Choices Control Costs and Preserve Access 53252 2Human Pheromones 3A Whats Purported Whats Supported A White Paper Published by The Sense of Smell Institute 53249 1
... for Medical Research (Burnham) have discovered a ... Sporadic Inclusion Body Myositis (sIBM). sIBM is ...men, causing muscles to gradually weaken and waste...known, but it is the most common muscle disease am...iliarity, it is probably underdiagnosed. This disc...
...cal Research Institute report that bats significan...In a lowland tropical rainforest in Panama, bats c...cts as do birds. This landmark study in the journa...ats and birds to protect plants via insect predati...dy by the authors suggested that bats were underes...
... University have pinpointed a small group of genes...w to produce a hormone that is key to their develo...ich hormone production in plants affects both a pl...nvironments. , Dr. Jose Alonso, assistant profes...nt biologists from NC State, Germany and the Czech...
Other Biology News:RING finger protein 5 may guide treatment for muscle disease in older adults 2RING finger protein 5 may guide treatment for muscle disease in older adults 3Smithsonian researchers show major role of bats in plant protection 2NC State researchers identify genes key to hormone production in plants 2
Rabbit Anti-QKI Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Acridinium Ester Trigger Solutions from Assay Designs/Stressgen Bioreagents
Mouse Anti-St. Louis encephalitis Monoclonal Antibody, Unconjugated, Clone 6B5A-2 from ABR-Affinity BioReagents
...bbit polyclonal to Kv4.2 Immunogen Synthetic pep...rresponding to amino acids 23-43 of Rat Kv4.2. Re...cted to cross-react with Human (100% identity with... Rabbit (100% identity with immunogen) and Ferret ...
Biology Products: